Literature DB >> 21940734

Adjuvant radiotherapy for a prostate cancer after renal transplantation and review of the literature.

Beatrice Detti1, Silvia Scoccianti, Davide Franceschini, Donata Villari, Daniela Greto, Samantha Cipressi, Angela Sardaro, Maria Zanassi, Tommaso Cai, Giampaolo Biti.   

Abstract

Renal transplant recipients are a population usually considered at a higher risk of malignancies, mostly skin cancer and lymphoproliferative disorder. In recent years, prostate cancer in renal transplant recipients has been becoming more frequent. This is probably due to the growing age and the longer survival of the transplanted patients. We report the case of a 50-year-old man with prostate cancer and renal allograft, who received radiotherapy after prostatectomy at the Institute of Radiotherapy of the University of Florence. Radiotherapy is part of the standard treatment for many cases of prostate cancer. According to the few series reported in the literature and also to our experience, radiation therapy is feasible also in renal transplant recipients with accurate treatment planning.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21940734     DOI: 10.1093/jjco/hyr133

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  3 in total

1.  Pelvic radiation therapy with volumetric modulated arc therapy and intensity-modulated radiotherapy after renal transplant: A report of 3 cases.

Authors:  Pérez Álvarez Sandra Ileana; Ramos Prudencio Rubi; Lozano Ruiz Francisco Javier; Macías González Monserrat Del Sagrario; Flores Balcazar Christian Haydeé
Journal:  Rep Pract Oncol Radiother       Date:  2020-04-28

2.  Iodine-125 prostate seed brachytherapy in renal transplant recipients: an analysis of oncological outcomes and toxicity profile.

Authors:  Nadine Beydoun; Joseph Bucci; David Malouf
Journal:  J Contemp Brachytherapy       Date:  2014-02-19

Review 3.  Haematuria in postrenal transplant patients.

Authors:  Ziting Wang; Anantharaman Vathsala; Ho Yee Tiong
Journal:  Biomed Res Int       Date:  2015-03-30       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.